Quince Therapeutics Inc. has released its financial results for the second quarter ended June 30, 2025. The company reported cash, cash equivalents, and short-term investments totaling $34.7 million. Quince anticipates that its existing cash will be sufficient to fund the company's development plan through the Phase 3 NEAT topline results into the second quarter of 2026, with potential to extend into the latter half of 2026 if financing warrants are exercised. Research and development expenses for the quarter were reported at $6.6 million, largely due to costs associated with the ongoing Phase 3 NEAT clinical trial and related manufacturing expenses. The company reported a net cash usage in operating activities of $21.0 million for the first half of 2025, primarily driven by a net loss of $31.1 million, adjusted for $9.9 million in non-cash items. Quince has completed enrollment in its pivotal Phase 3 NEAT clinical trial, with topline results expected in the first quarter of 2026. The company has also entered into a strategic partnership with Option Care Health to support the commercial launch of its lead asset, eDSP, in the U.S. Quince remains confident in delivering topline results and plans for an NDA submission in the second half of 2026, contingent on positive study results.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811018550) on August 11, 2025, and is solely responsible for the information contained therein.
Comments